Welcome to our dedicated page for CONEXEU SCIENCES SEC filings (Ticker: CNXU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CONEXEU SCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CONEXEU SCIENCES's regulatory disclosures and financial reporting.
Conexeu Sciences Inc. reported the cash exercise of common stock purchase warrants and related share issuances. On June 4, 2026, the company issued 416,667 common shares for gross proceeds of about $166,667 under a warrant exercise incentive program and granted 416,667 new Incentive Warrants.
The Incentive Warrants allow holders to buy one additional share each at $2.30 for 36 months. After this exercise, 410,338 Program Warrants remained outstanding and common shares outstanding were 26,658,330. On June 8, 2026, Conexeu issued 100,000 Performance Warrant Shares at $0.001 per share, raising $100 and bringing total common shares outstanding to 26,758,330.
Conexeu Sciences Inc. insider entity N3GU Investments LLC, over which reporting person Michael G. Wright has sole voting and dispositive power, exercised 400,000 Performance Warrants to acquire 400,000 shares of Common Stock at $0.001 per share, all held indirectly.
Following the transactions, N3GU Investments LLC indirectly held 1,898,048 shares of Common Stock and 500,000 remaining Performance Warrants. The original grant covered 900,000 Performance Warrants, with future vesting tied to an >$80,000,000 market capitalization milestone and submission of a 510(k) application to the U.S. Food and Drug Administration.
Conexeu Sciences Inc. insider Michael G. Wright filed an initial Form 3 showing his beneficial ownership in CNXU. He reports indirect ownership of 1,498,048 shares of common stock through N3GU Investments LLC, over which he has sole voting and dispositive power, and direct ownership of 750,000 common shares.
Wright also holds derivative securities: 900,000 Performance Warrants with a $0.001 exercise price expiring on June 5, 2030, 78,595 Warrants with a $0.80 exercise price expiring on January 21, 2027, and 50,000 Stock Options with a $0.40 exercise price expiring on June 9, 2030. The stock options and standard warrants vested immediately on their respective grant dates.
Of the Performance Warrants, 150,000 have vested. The remaining 750,000 will vest in three 250,000-warrant tranches tied to specific milestones, including a North American stock exchange listing, a period of at least 20 consecutive trading days at a market capitalization above $80,000,000, and submission of a 510(k) application to the U.S. Food and Drug Administration.
Conexeu Sciences Inc. director Lorenc Zbigniew Paul filed an initial Form 3 reporting his ownership in the company. The filing shows that he directly holds 422,148 shares of Common Stock following the reported position. The entry reflects holdings only, with no buy or sell transaction reported.
Conexeu Sciences Inc. is registering the resale of up to 9,481,123 shares of common stock that may be sold over time by existing securityholders in connection with a planned direct listing on the Nasdaq Capital Market under the symbol “CNXU.” These shares include stock issued for debt settlement, a private placement, a business advisory agreement, and a Regulation Crowdfunding offering, plus shares issuable upon exercise of related warrants. The company itself is not selling shares in this registration and will only receive cash if holders exercise warrants. Conexeu is an early-stage medical device company developing CXU™, a collagen-based scaffold device candidate still in preclinical development with no regulatory clearances or product revenue. As of April 16, 2026, 20,916,173 shares of common stock were outstanding. The direct listing is conditional on Nasdaq approval, and the company highlights substantial risks typical of an emerging growth, pre-revenue business relying on a single device candidate.